Ramaswamy Govindan
YOU?
Author Swipe
View article: Supplementary Figure 1 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer
Supplementary Figure 1 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer Open
Supplementary Figure 1 shows the sample selection process
View article: Supplementary Table 4 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer
Supplementary Table 4 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer Open
Supplementary Table 4 shows the association between finer composite sleep score and EAC risk
View article: Supplementary Table 8 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer
Supplementary Table 8 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer Open
Supplementary Table 8 shows the joint associations between composite sleep score and genetic risk with EAC risk
View article: Supplementary Table 9 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer
Supplementary Table 9 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer Open
Supplementary Table 9 shows the additive interaction between composite sleep score and genetic risk with EAC risk
View article: Supplementary Table 6 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer
Supplementary Table 6 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer Open
Supplementary Table 6 shows the association between composite sleep score and EAC risk with deaths as competing events
View article: Supplementary Table 2 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer
Supplementary Table 2 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer Open
Supplementary Table 2 shows the weights used to construct the weighted sleep score
View article: Supplementary Table 1 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer
Supplementary Table 1 from Sleep Behaviors, Genetic Predispositions, and Risk of Esophageal Cancer Open
Supplementary Table 1 shows the associations between SNPs and EAC risk
View article: 648 A pilot study to evaluate the combination of zimberelimab, domvanalimab and etrumadenant in patients with previously treated non-small cell lung cancer (NSCLC)
648 A pilot study to evaluate the combination of zimberelimab, domvanalimab and etrumadenant in patients with previously treated non-small cell lung cancer (NSCLC) Open
View article: Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma
Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma Open
Advanced-stage lung squamous cell carcinoma (LUSC) remains a therapeutic challenge. Although immune checkpoint inhibitors (ICIs) have revolutionized LUSC treatment, only a small subset of LUSC patients can achieve durable clinical benefits…
View article: Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer
Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer Open
View article: Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures
Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures Open
Lung adenocarcinomas (LUAD) are a pressing global health problem with enduring lethality and rapidly shifting epidemiology. Proteogenomic studies integrating proteomics and post-translational modifications with genomics can identify clinic…
View article: Table 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Table 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Key comparison overview of single- and multiarm lete-cel NSCLC trials.
View article: Table 3 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Table 3 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Safety results: grade ≥3 and total AESIa and SAE. Single-arm study (mITT population).
View article: Supplementary Figure 3 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 3 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 3. Multi-arm study – Patient disposition
View article: Data from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Data from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Purpose:The study aims to evaluate the safety, tolerability, and antitumor response of letetresgene autoleucel (lete-cel), genetically modified autologous T cells expressing a T-cell receptor specific for New York esophageal squamous cell …
View article: Figure 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Figure 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Patient attrition and NY-ESO-1 and LAGE-1a expression profiles in the multiarm study. A, Patient attrition for multiarm study. A total of 1,698 patients in the multiarm study were screened and signed the informed consent form. Out o…
View article: Supplementary Figure 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 1. Patient journey
View article: Table 4 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Table 4 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Safety results: grade ≥3 and total AESIa and SAE. Multiarm study (mITT population).
View article: Supplementary Table 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Table 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Table 2. Representativeness of Study Participants
View article: Supplementary Figure 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figure 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Figure 2. Single-arm study – Patient disposition
View article: Supplementary Table 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Table 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Table 1. Key eligibility criteria
View article: Figure 3 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Figure 3 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Cellular kinetics profile by patient in the single- and multiarm studies. A, Single-arm study. Cellular kinetics profile at first infusion by patient and responder status truncated at 12 weeks (available data), mITT population. B…
View article: Supplementary Table 3 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Table 3 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Supplementary Table 3. Grade ≥3 and total TEAEs
View article: Figure 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Figure 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Patient tumor responses in the single- and multiarm studies. A, Best overall response in the single- and multiarm studies (confirmed). In the single-arm study, data following first infusion only. One patient did not have measurable …
View article: Table 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Table 2 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Patient characteristics: tumor stage and histology, prior therapy, LDR, and lete-cel treatment (mITT population).
View article: Impact of stain variation and color normalization for prognostic predictions in pathology
Impact of stain variation and color normalization for prognostic predictions in pathology Open
View article: Patient-generated health data: Impact on promoting patient-centered point of care tobacco treatment in patients with cancer
Patient-generated health data: Impact on promoting patient-centered point of care tobacco treatment in patients with cancer Open
Introduction: Guideline-based tobacco treatment is infrequently offered. Electronic health record-enabled patient-generated health data (PGHD) has the potential to increase patient treatment engagement and satisfaction. Methods: We evaluat…
View article: Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer Open
Purpose: The study aims to evaluate the safety, tolerability, and antitumor response of letetresgene autoleucel (lete-cel), genetically modified autologous T cells expressing a T-cell receptor specific for New York esophageal squamous cell…
View article: Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer
Basal cell of origin resolves neuroendocrine–tuft lineage plasticity in cancer Open
Summary paragraph Neuroendocrine and tuft cells are rare, chemosensory epithelial lineages defined by expression of ASCL1 and POU2F3 transcription factors, respectively 1,2 . Neuroendocrine cancers, including small cell lung cancer (SCLC),…
View article: Length-scale study in deep learning prediction for non-small cell lung cancer brain metastasis
Length-scale study in deep learning prediction for non-small cell lung cancer brain metastasis Open